Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Trends Immunol. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:
PMCID: PMC2788100

CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns


It is now well accepted that the innate immune system recognizes both damage (or danger)- and pathogen-associated molecular patterns (DAMP and PAMP, respectively) through pattern recognition receptors, such as Toll-like receptors (TLR) and/or Nod-like receptors (NLR). Less clear are whether and how the response to PAMP and DAMP are differentially regulated. The answers may reveal whether the primary goal of the immune system is to defend against infections or to alert the host of tissue injuries. We demonstrated recently that the host response to DAMP is controlled by a DAMP-CD24-Siglec axis. Here we propose a key role for the CD24-Siglec pathway in discriminating between DAMPs and PAMPs.


According to popular myth, Ilya Metchnikoff first demonstrated cell-mediated immunity by sticking a rose thorn into starfish larvae. Though this was taught to generations of immunology students as a response to a foreign body, it may in fact be a host response to injury. The fact that the latter possibility was usually over-looked reflects the desire of immunologists to view the immune system as the host’s machinery for self-nonself discrimination based on the precise recognition of antigens by clonally distributed receptors on T and B lymphocytes.

Over 20 years ago, in his introduction to the Cold Spring Harbor Quantitative Biology Symposium 1, Charles Janeway elegantly outlined a case against what he called the “Landsteinian Fallacy”, namely, all antigenic variations that are recognizable by antibodies must be equally immunogenic. He proposed pattern recognition as the basis for initiation of an immune response against the infectious nonself, in progressively more definitive terms 14. At this time, one of us (YL) was privileged to be working in the Janeway laboratory and showed that components from microbes (including viruses, bacteria, and yeast) can induce costimulatory activity on antigen-presenting cells (APC) 5. We further showed that induction of the costimulatory molecule B7 (CD80) explained 6 our earlier observation 7 of “immunological help for the cytotoxic T cell response” by activated B cells. These observations validated the Janeway postulate that innate immunity sets the stage for adaptive immunity through its induction of costimulatory molecules on the APC.

Subsequently, Medzhitov assayed induction of the costimulatory molecule B7 when he cracked the code of microbial pattern recognition by Toll-like receptors (TLR) with Janeway 8. This study marked a paradigm shift in the concept of immune recognition. A recent account of the exciting time and the periods that followed was recently provided by Medzhitov 9 in commemoration of the 20 year’s anniversary of the publication of Janeway’s classic assay. Readers are therefore referred to this review.

As a distinct repudiation of clonal receptor-based immune recognition, Matzinger proposed what is known as the “danger theory” in 1994 10. In essence, she argued that the immune system does not care about discriminating self- from nonself, but rather dangerous from non-dangerous signals. She acknowledged the difficulty in defining “danger” but equated it to tissue injury occurring in some context. While both Janeway and Matzinger attempted to invoke a nonclonal event as the on-off switch of immunity, they predicted very different purposes of the immune response: to combat infection or to alert the host to tissue injuries. Although tissue injury will certainly occur during infection, those in the Janeway school of thoughts had difficulties reconciling with the danger theory for two reasons. First, from an evolutionary perspective, it is likely that infections impose selective pressure to shape the immune system. Second, the “danger” of the danger theory is that it would predict that the host mounts an immune response whenever tissue injury occurs. Nevertheless, Nature surprised us all when the molecular mechanisms of the host response to pathogen- and danger-associated molecular patterns were revealed over subsequent years.

Shared mechanisms in the recognition of DAMPs and PAMPs

Tissue injuries often lead to release of intracellular components that are collectively called DAMP. Only a few selective examples are provided herein to illustrate the shared mechanisms for recognition of DAMPs and PAMPs. Readers are referred to recent reviews among many outstanding ones for more thorough analyses of DAMPs 11,12.

The best characterized DAMPs in the cytoplasm are the heat-shock proteins (HSPs). It has long been recognized that HSPs can promote immune responses. In addition to their role in promoting antigen-presentation 13,14, some HSP also promote dendritic cell (DC) maturation and induce inflammatory cytokines which in turn recruit lymphocytes and myeloid cells into lymph nodes 15,16 Interestingly, these two functions of the HSPs appear to be fulfilled via distinct mechanisms. The cross-presentation of antigens is mainly achieved by interaction between the HSP and CD91 17,18. On the other hand, accumulating evidence supports an important role for the TLR-MyD88-NFkB pathway, which was the classic pathway for PAMP recognition, in the recognition of HSPs in the context of DAMP recognition 1921.

In addition to the cytoplasm components, nuclear components from damaged cells have also been demonstrated to activate the innate immune system. High mobility group box 1 (HMGB1) is a nuclear protein that was initially studied for its role in gene transcription 2224. Interestingly, HMGB1 is actively secreted from monocytes, macrophages, and DC following its acetylation 25, 26,27. It is also rapidly released by all cell types during necrosis 28. Extracellular HMGB1 interacts with a number of cellular receptors, such as RAGE 29,30, TLR4 31, TLR2 32, and TLR9 33 when HMGB1 is complexed with DNA, Importantly, HMGB1 activates NF-kB via a TLR-MyD88-dependent mechanism 3436, which is also very similar to pattern recognition associated with infection.

The third category of DAMPs is low molecular weight adjuvants highly concentrated in the cytosol. A systemic approach by Shi et al. demonstrated uric acid as the major source of low molecular weight adjuvant from necrotic cells for cross-priming CD8 T cells 37. Monosodium urate forms crystal and was demonstrated to cause lysosomal damage and activation of Nalp3 38, which belongs to the family of NOD-like (NLR) receptors 39. Like TLR, prototypic NLRs, NOD1 and NOD2 regulate host response to microbial components 40. Therefore, although much of the signaling pathways remain to be identified, the major categories of DAMPs studied so far appear to use the same receptors that were characterized for PAMPs.

The unexpected convergence of molecular pathways responsible for recognition of PAMPs and DAMPs raised the question of whether the host really treats PAMPs and DAMPs in fundamentally the same way in terms of the intensity and quality of innate and adaptive immune responses. Unlike those with persistent or chronic infections, those hosts that survive acute infections are often followed by sterilizing immunity. On the other hand, tissue injuries alone are not normally followed by devastating autoimmune diseases. For example in the context of cancer immunity, the interaction between HMGB1 and TLR4 is essential for DC activation, priming of antigen-specific T cells, and resistance to cancer cells 36. However, despite the fact that tumor lysates are expected to contain a large load of self-antigens, autoimmune side effects were not reported 36. In the case of HSPs, it has been reported that a co-injection of HSP70, which is also released in conjunction with necrosis, induced diabetes in mice that expressed a T cell receptor (TCR) specific for a viral antigen transgenically expressed in pancreatic islet β-cells19. It should be noted, however, that in mice with a normal T-cell repertoire, no autoimmune disease has been reported to be elicited by the same treatment regimen19. Likewise, although ectopic expression of membrane-bound GP96 (another HSP)has been demonstrated to trigger signs of autoimmune diseases, the autoimmune phenotype is relatively modest 41.

The fortunate modesty of autoimmune diseases triggered by DAMP is not fully understood but at least two explanations can be invoked. The first involves the well documented mechanism of immune tolerance, such as negative selection of T, B cell receptor repertoire, clonal anergy, activation-induced cell death of mature T cells and the action of suppressor or regulatory cells. Although relatively under-studied, a second intriguing possibility is that the host may have developed a mechanism to ameliorate the response to DAMPs. Our recent studies on the CD24-Siglec G/10 pathway described below are consistent with this notion.

The CD24-Siglec G/10 pathway discriminates between DAMP vs. PAMP

CD24 is also known as the heat-stable antigen (HSA) 42. It is expressed as a glycosyl-phosphatidyl-inositol (GPI)-anchored molecule 43 and has a wide distribution in diverse cell lineages 44. Because of the tendency of CD24 to be expressed on immature cells, it has also been used along with other molecules as a stem cell marker during lymphocyte differentiation. The first function associated with CD24 is a costimulatory activity for antigen-specific T cell responses 4547. In vivo studies indicated that, as a costimulator for T cell activation in lymphoid organs, CD24 is redundant but becomes essential in the absence of CD28 48,49. This would not be the case for local target organs that are not as “costimulatory ligand rich” such as the central nervous system. Consistent with this notion, we demonstrated that mice with a targeted mutation of CD24 are completely resistant to induction of experimental autoimmune encephalomyelitis (EAE) 50, 51. Polymorphisms of human CD24 are associated with risk and progression of several autoimmune diseases 5256.

While all the above findings can be interpreted in the context of an immune enhancing effect of the CD24 gene, two lines of recent observations pointed to another important role for CD24 in negative regulation of the immune response. First, when wild-type T cells were transferred into lymphopenic, CD24-deficient hosts, they underwent vigorous homeostatic proliferation 57. In fact, the transferred syngeneic wild-type T cells killed the majority of the CD24-deficient recipients within 2 weeks, possibly due to a “cytokine storm” associated with excessive T cell activation. Further analysis of this model system implicated a role for CD24 on recipient DC in the suppression of excessive homeostatic proliferation 57. Second, using an acetaminophen-induced liver injury model, we demonstrated that germline mutation of CD24 dramatically increased susceptibility to necrosis of liver cells 58.

To dissect the molecular basis of this negative regulatory function, we identified molecules that co-immunoprecipitated with CD24 using mass spectrometry. An association between CD24 and HMGB1 was confirmed by reciprocal immunoprecipitation. Likewise, both approaches also revealed interaction between CD24 and Hsp70 or Hsp90. Furthermore, using high affinity neutralizing anti-HMGB1 antibodies 59, we were able to demonstrate a critical role for HMGB1 in the lethal inflammatory response in the CD24-deficient mice.

Theoretically, CD24 may repress host the response to DAMPs by two mechanisms. First, CD24 may trap DAMPs and thus prevent them from binding to their agonistic receptors such as TLR or NLR. In addition, CD24 might actively repress the host response to DAMPs. Since CD24 is a GPI-anchored molecule that does not have an intracellular domain, we reasoned that CD24 negatively regulates responses to HMGB1 by interacting with other proteins that recognize saccharides on CD24. We were particularly intrigued by members of the Siglec families that have Ig-like type I transmembrane proteins with an IgV-like domain binding to a sialic acid-containing structure 60,61. Currently, there are at least 13 Siglecs in humans and 8 in mice. Except for Sn and Siglec H, all other known Siglecs have immunoreceptor tyrosine-based inhibitory motifs (ITIM) or ITIM-like regions in their intracellular domains. As such, it is expected that they have the capacity to recruit the phosphatases SHP-1, SHP2, and possibly SHIP.

Our analysis of a panel of Siglec fusion proteins indicated that CD24 binds to Siglec G in mice and its human homologue Siglec 10 58. The interaction between mouse Siglec G and CD24 is confirmed by immunoprecipitation. Mice with a targeted deletion of the entire Siglec G coding region62 phenocopy CD24-deficient mice in their susceptibility to acetaminophen-induced liver injury 58. Further, we demonstrated that Siglec G physically associates with CD24, through which it also associates with DAMPs, such as HMGB1, HSP 70, and HSP90 and repressed the response to these DAMPs. The effect is reflected at the level of NF-kB activation 58. Importantly, at both cellular or organism levels, neither CD24 nor Siglec G regulate the inflammatory response to lipopolysaccharide (LPS) or Poly I:C (TLR4 and TLR3 agonists respectively), the two PAMPs tested so far. Based on these observations, we propose a simple model by which the CD24-Siglec G/10 discriminate DAMP vs. PAMP by selectively repressing the host response to DAMPs (Figure 1).

Figure 1
The CD24-Siglec G (mouse) or -Siglec 10 (human) pathway discriminates between Pathogen-Associated Molecular Patterns (PAMPs) from Danger-Associated Molecular Patterns (DAMPs) by selective repression of the host response to DAMPs. We propose that DAMPs ...

In essence, we propose CD24 as the main negatively-signaling DAMP receptor whose function is to antagonize the stimulatory DAMP receptors. In its simplest form, we propose that DAMPs cross-link TLR and/or NLR with the CD24-Siglec G/10 complex and thereby brings Siglec-associated SHP-1 to the signaling complex involved in NF-kB activation. This can be achieved by distinct binding sites on DAMPs to either CD24 or TLR/NLR. Alternatively, DAMPs may be multimerized to allow simultaneous binding to multiple receptors even if the binding sites overlap.

Several pieces of evidence support this model. First, CD24 might be uniquely suitable for interacting with a large array of DAMPs because of its extensive glycosylations. In addition to HMGB1 and HSP, CD24 is associated with other intracellular components such as nucleolin 58. Second, CD24 is the high affinity ligand for Siglec G/10 58. In contrast, CD24 may have additional receptors as targeted mutation of Siglec G/10 only partially reduces the binding of CD24-Fc fusion protein to spleen cells 58. It is therefore possible that additional signaling pathways, including but not limited to members of the Siglec family, may be recruited to discriminate large arrays of DAMPs from PAMPs. Thirdly, we have demonstrated that for the two best studied DAMPs and two well characterized PAMPs, the CD24-Siglec G/10 pathway selectively represses the response to DAMP but not PAMP, even though HSP, HMGB1 and LPS all interact with TLR4. However, it should be noted that the role of the CD24-Siglec G/10 pathway is demonstrated mostly by genetic studies, so biochemical analyses are urgently needed to provide mechanistic insights. Likewise, the DAMPs and PAMPs tested are fairly limited in scope, so further studies are needed to demonstrate the general applicability of this model.


Conceptually, identification of a pathway that selectively represses host responses to DAMPs but not PAMPs suggests that the two inflammatory stimuli are treated very differently by the immune system. As such, it is no longer tenable to consider PAMPs as part of a danger signal unleashed during tissueinjury. Practically, identification of the negative regulator pathway might provide us with novel approaches to amplify the local inflammatory response in order to achieve optimal adaptive immunity for cancer therapy. It is of interest that CD24 is essential for the development of EAE and genetic studies with human CD24 polymorphisms suggest its involvement in multiple autoimmune diseases 63. If the role for CD24 in autoimmune diseases can be generalized, then the targeting of CD24 might expand the local immune response while conveying resistance to autoimmune diseases, which is a major issue in cancer immunotherapy 64. Conversely, enhancing CD24-signaling might provide added protection from inflammation and/or autoimmune disease following acute tissue injury or trauma. Finally, it has not escaped our attention that many viruses and most pathogenic bacteria express sialidase as their virulence factors 65,66. By cleaving off sialic acid from CD24, pathogen-expressed sialidase might abrogate the negative regulation of DAMPs. This could provide a novel explanation for the massive inflammation associated with these pathogens.


This work is supported by grants from National Institute of Health (CA58033 and AI64350). We thank Molly Liu for critical reading of the manuscript. We dedicate this work to the memory of Dr. Charles A. Janeway, Jr.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54:1–13. [PubMed]
2. Janeway C. Immunogenicity signals 1,2,3 … and 0 [news] Immunol Today. 1989;10 (9):283–286. [PubMed]
3. Janeway CA., Jr The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today. 1992;13 (1):11–16. [PubMed]
4. Janeway CA, Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell. 1994;76 (2):275–285. [PubMed]
5. Liu Y, Janeway CA., Jr Microbial induction of co-stimulatory activity for CD4 T-cell growth. Int Immunol. 1991;3 (4):323–332. [PubMed]
6. Wu Y, Liu Y. Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4+ T-cell help in CD8+ T-cell responses. Curr Biol. 1994;4 (6):499–505. [PubMed]
7. Liu Y, Mullbacher A. Activated B cells can deliver help for the in vitro generation of antiviral cytotoxic T cells. Proc Natl Acad Sci U S A. 1989;86 (12):4629–4633. [PubMed]
8. Medzhitov R, et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388 (6640):394–397. [PubMed]
9. Medzhitov R. Approaching the asymptote: 20 years later. Immunity. 2009;30 (6):766–775. [PubMed]
10. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045. [PubMed]
11. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8 (4):279–289. [PMC free article] [PubMed]
12. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5 (4):331–342. [PubMed]
13. Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol. 1994;6 (5):728–732. [PubMed]
14. Srivastava PK, et al. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 1994;39 (2):93–98. [PubMed]
15. Basu S, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol. 2000;12 (11):1539–1546. [PubMed]
16. Binder RJ, et al. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c(+) cells In vivo. J Immunol. 2000;165 (11):6029–6035. [PubMed]
17. Basu S, et al. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 2001;14 (3):303–313. [PubMed]
18. Binder RJ, et al. CD91: a receptor for heat shock protein gp96. Nat Immunol. 2000;1 (2):151–155. [PubMed]
19. Millar DG, et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med. 2003;9 (12):1469–1476. [PubMed]
20. Vabulas RM, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem. 2002;277 (17):15107–15112. [PubMed]
21. Warger T, et al. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem. 2006;281 (32):22545–22553. [PubMed]
22. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999;19 (8):5237–5246. [PMC free article] [PubMed]
23. Goodwin GH, et al. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem. 1973;38 (1):14–19. [PubMed]
24. Weir HM, et al. Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 1993;12 (4):1311–1319. [PubMed]
25. Bonaldi T, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22 (20):5551–5560. [PubMed]
26. Abraham E, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165 (6):2950–2954. [PubMed]
27. Wang H, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285 (5425):248–251. [PubMed]
28. Scaffidi P, et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418 (6894):191–195. [PubMed]
29. Hori O, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995;270 (43):25752–25761. [PubMed]
30. Palumbo R, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol. 2007;179 (1):33–40. [PMC free article] [PubMed]
31. Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282 (5396):2085–2088. [PubMed]
32. Park JS, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279 (9):7370–7377. [PubMed]
33. Tian J, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8 (5):487–496. [PubMed]
34. Tsung A, et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med. 2007;204 (12):2913–2923. [PMC free article] [PubMed]
35. Tsung A, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005;201 (7):1135–1143. [PMC free article] [PubMed]
36. Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13 (9):1050–1059. [PubMed]
37. Shi Y, et al. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425 (6957):516–521. [PubMed]
38. Hornung V, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9 (8):847–856. [PMC free article] [PubMed]
39. Ting JP, et al. NLRs at the intersection of cell death and immunity. Nat Rev Immunol. 2008;8 (5):372–379. [PubMed]
40. Inohara N, et al. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr Opin Microbiol. 2002;5 (1):76–80. [PubMed]
41. Liu B, et al. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci U S A. 2003;100 (26):15824–15829. [PubMed]
42. Springer T, et al. Monoclonal xenogeneic antibodies to murine cell surface antigens: identification of novel leukocyte differentiation antigens. Eur J Immunol. 1978;8 (8):539–551. [PubMed]
43. Pierres M, et al. Evidence that murine hematopoietic cell subset marker J11d is attached to a glycosyl-phosphatidylinositol membrane anchor. Eur J Immunol. 1987;17 (12):1781–1785. [PubMed]
44. Rougon G, et al. The murine heat-stable antigen: a differentiation antigen expressed in both the hematolymphoid and neural cell lineages. Eur J Immunol. 1991;21 (6):1397–1402. [PubMed]
45. Liu Y, Janeway CAJ. Cells that present both specific ligand and the costimulatory activity are the most efficient inducer of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA. 1992;89:3845–3849. [PubMed]
46. Liu Y, et al. Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med. 1992;175 (2):437–445. [PMC free article] [PubMed]
47. Liu Y, et al. Co-stimulation of murine CD4 T cell growth: cooperation between B7 and heat-stable antigen [published erratum appears in Eur J Immunol 1993 Mar;23(3):780] Eur J Immunol. 1992;22 (11):2855–2859. [PubMed]
48. Liu Y, et al. Distinct costimulatory molecules are required for the induction of effector and memory cytotoxic T lymphocytes. J Exp Med. 1997;185 (2):251–262. [PMC free article] [PubMed]
49. Wu Y, et al. CD28-independent induction of T helper cells and immunoglobulin class switches requires costimulation by the heat-stable antigen. J Exp Med. 1998;187 (7):1151–1156. [PMC free article] [PubMed]
50. Bai XF, et al. The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis. J Clin Invest. 2000;105 (9):1227–1232. [PMC free article] [PubMed]
51. Bai XF, et al. CD24 Controls Expansion and Persistence of Autoreactive T Cells in the Central Nervous System during Experimental Autoimmune Encephalomyelitis. J Exp Med. 2004;200 (4):447–458. [PMC free article] [PubMed]
52. Otaegui D, et al. CD24 V/V is an allele associated with the risk of developing multiple sclerosis in the Spanish population. Mult Scler. 2006;12 (4):511–514. [PubMed]
53. Rueda B, et al. Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol. 2008;35 (5):850–854. [PubMed]
54. Sanchez E, et al. Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2007;56 (9):3080–3086. [PubMed]
55. Wang L, et al. A di-nucleotide deletion in CD24 confers protection against autoimmune diseases. Plos Genetics. 2007;3:e49. [PubMed]
56. Zhou Q, et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci U S A. 2003;100 (25):15041–15046. [PubMed]
57. Li O, et al. Massive and destructive T cell response to homeostatic cue in CD24-deficient lymphopenic hosts. J Exp Med. 2006;203 (7):1713–1720. [PMC free article] [PubMed]
58. Chen GY, et al. CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses. Science. 2009;323:1722–1725. [PMC free article] [PubMed]
59. Zhou H, et al. Generation of monoclonal antibodies against highly conserved antigens. PLoS ONE. 2009;4 (6):e6087. [PMC free article] [PubMed]
60. Crocker PR, et al. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7 (4):255–266. [PubMed]
61. Varki A, Angata T. Siglecs--the major subfamily of I-type lectins. Glycobiology. 2006;16 (1):1R–27R. [PubMed]
62. Ding C, et al. Siglecg limits the size of B1a B cell lineage by down-regulating NFkappaB activation. PLoS ONE. 2007;2 (10):e997. [PMC free article] [PubMed]
63. Liu Y, Zheng P. CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. Trends Immunol. 2007;28 (7):315–320. [PubMed]
64. Phan GQ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen-4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372–8377. [PubMed]
65. Drzeniek R. Viral and bacterial neuraminidases. Curr Top Microbiol Immunol. 1972;59:35–74. [PubMed]
66. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev. 2001;65(2):187–207. first page, table of contents. [PMC free article] [PubMed]